{"id":987500946,"date":"2025-01-08T17:00:30","date_gmt":"2025-01-08T17:00:30","guid":{"rendered":"https:\/\/boracdmo.com\/bora-biologics-announces-strategic-collaboration-to-accelerate-key-cmc-development-of-dotbios-tri-specific-antibody-to-treat-cancer\/?lang=en"},"modified":"2025-07-25T13:23:52","modified_gmt":"2025-07-25T13:23:52","slug":"bora-biologics-announces-strategic-collaboration-to-accelerate-key-cmc-development-of-dotbios-tri-specific-antibody-to-treat-cancer","status":"publish","type":"post","link":"https:\/\/boracdmo.com\/bora-biologics-announces-strategic-collaboration-to-accelerate-key-cmc-development-of-dotbios-tri-specific-antibody-to-treat-cancer\/","title":{"rendered":"Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio\u2019s Tri-Specific Antibody to Treat Cancer"},"content":{"rendered":"<p style=\"text-align: center;\"><strong>Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio\u2019s Tri-Specific Antibody to Treat Cancer<\/strong><\/p>\n<p>Bora Biologics, a fast-growing division of leading contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, today announced that it will support DotBio, a Singaporean biopharmaceutical company specializing in next-generation antibody therapies, in the development and manufacturing of DotBio\u2019s lead asset, a novel tri-specific antibody, code name DB007, against undisclosed cancer targets.<\/p>\n<p>Bora will support the development of DotBio\u2019s lead asset, including its chemistry, manufacturing and controls (CMC) strategy, through to clinical development from its 48,400-square-foot (4,500-square-meter) centre-of-excellence in Zhubei, Taiwan.<\/p>\n<p>\u201cBora Biologics offers a tailored development and manufacturing plan that provides end-to-end support for our client\u2019s development programs,\u201d commented Bobby Sheng, Chairman and CEO of Bora Group. \u201cWith operations up and running in Zhubei, Bora\u2019s team of experts are ready to deliver high-yield processes together with the sophisticated program management capabilities necessary to successfully develop even the most challenging molecules.\u201d<\/p>\n<p>Ignacio Asial, Ph.D., Founder and CEO of DotBio said, \u201cWe chose Bora Biologics as our development partner because of its expertise in early-phase biologics development and solid track record in high-yield manufacturing of multi-specific antibody molecules. Bora\u2019s early-clinical manufacturing facilities in Taiwan align perfectly with our current IND-development stage, while their large-scale, commercial-stage manufacturing and fill-and-finish facilities in the United States will support our goal to treat patients globally. I am thrilled to be working hand-in-hand with one of the best CDMO partners in Asia.\u201d<\/p>\n<p>Bora Biologics\u2019 facility in Zhubei provides early-stage discovery research support, lead candidate screening, in vitro assays, and biochemical\/physical assays, as well as preparation and purification of the most complex proteins, and monoclonal, bispecific and multi-specific antibodies and other recombinant proteins for research purposes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bora Biologics Announces Strategic Collaboration to Accelerate Key CMC Development of DotBio\u2019s Tri-Specific Antibody to Treat Cancer Bora Biologics, a fast-growing division of leading contract development and manufacturing organization (CDMO), Bora Pharmaceuticals, today announced that it will support DotBio, a Singaporean biopharmaceutical company specializing in next-generation antibody therapies, in the development and manufacturing of DotBio\u2019s [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":987500948,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[58],"tags":[69],"class_list":["post-987500946","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","tag-business"],"aioseo_notices":[],"acf":[],"_links":{"self":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987500946","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/comments?post=987500946"}],"version-history":[{"count":0,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/posts\/987500946\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media\/987500948"}],"wp:attachment":[{"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/media?parent=987500946"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/categories?post=987500946"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/boracdmo.com\/en\/wp-json\/wp\/v2\/tags?post=987500946"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}